- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Study Overview
Status
Conditions
- Melanoma
- Sarcoma
- Kidney Cancer
- Adenocarcinoma
- Renal Cell Carcinoma
- Cervical Cancer
- Acute Myeloid Leukemia
- Stomach Cancer
- Breast Cancer
- Head and Neck Neoplasms
- Nasopharyngeal Carcinoma
- Glioblastoma
- Astrocytoma
- Multiple Myeloma
- Colorectal Cancer
- Pancreatic Cancer
- Esophageal Cancer
- Small Bowel Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Lung Cancer
- Bone Cancer
- Osteosarcoma
- Rectal Cancer
- Prostate Cancer
- Waldenstrom Macroglobulinemia
- Acute Lymphoblastic Leukemia
- Brain Tumor
- Neuroendocrine Tumors
- Mesothelioma
- Non Hodgkin Lymphoma
- Vulvar Cancer
- Cholangiocarcinoma
- Bile Duct Cancer
- Chronic Myeloid Leukemia
- Bladder Cancer
- Skin Cancer
- Chondrosarcoma
- Colon Cancer
- Gestational Trophoblastic Tumor
- Sarcoma, Kaposi
- Thyroid Cancer
- Anal Cancer
- Liposarcoma
- Ureter Cancer
- Liver Cancer
- Pheochromocytoma
- Vaginal Cancer
- Brain Stem Neoplasms
- Carcinoid Tumor
- Penile Cancer
- Tongue Cancer
- Cancer of Pancreas
- Synovial Sarcoma
- Adrenal Cancer
- Pharynx Cancer
- Larynx Cancer
- Parathyroid Neoplasms
- Multiple Endocrine Neoplasia
- Uterine Cancer
- Adenocystic Carcinoma
- Appendix Cancer
- Sarcoma,Soft Tissue
- CNS Cancer
- Esophagus Cancer
- Cancer of Colon
- Testis Cancer
- Testicular Cancer
- Parotid Tumor
- Salivary Gland Cancer
- Hepatic Cancer
- Unknown Primary Tumors
- Cancer, Advanced
- Thymus Cancer
- Small Cell Carcinoma
- Pulmonary Carcinoma
Intervention / Treatment
Detailed Description
This is a master observational trial (MOT). Anyone who has been diagnosed with advanced cancer is eligible as long as they are a candidate for treatment. Each patient will receive testing and treatment as determined by patient in consultation with physician. ROOT will proceed in two directions: (1) Validation Cohorts. These patients will demonstrate the ability of the MOT to prospectively collect data using the same protocol and related documents, standardized data elements and processes, and accepted scientific endpoints; and (2) Analysis Cohorts. The modular nature of the study allows collection of RWD ranging from diagnosis only to the full treatment course of the of the patient. Patients are grouped to allow focused data collection or a specific analysis. Analysis cohorts can be created from patients already enrolled in ROOT or be defined prospectively. Because of the ongoing advancements of molecular based oncology, this trial allows a detailed focus on molecular testing as part of any cohort.
Data is reported by the group that is most qualified to provide this information and is proved, at point of care, using standardized data elements and processes. Physicians will report diagnosis, molecular characteristics, staging, disease burden, significant comorbidities, treatment response, and medical decision making. Molecular testing (reports and details) will be requested from testing laboratories. Any diagnostic films will be received digitally from the location the study was performed. Research staff assist in data entry and providing physicians needed data as part of the regular workflow to allow point-of-care reporting.
The Validation Cohorts and Analysis Cohorts may run sequentially or in parallel with each other.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Judy Taylor
- Phone Number: (801) 396-5190
- Email: judy.taylor@taprootco.com
Study Contact Backup
- Name: Lori Miles
- Phone Number: (801) 396-5190
- Email: lori.miles@taprootco.com
Study Locations
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Recruiting
- Teton Cancer Institute
-
Contact:
- Manager of Oncology Services
- Phone Number: 208-356-9559
- Email: landerson5@tetoncancer.com
-
Contact:
- Jeffery Hancock, MD
- Phone Number: 208-356-9559
-
Principal Investigator:
- Jeffery Hancock, MD
-
-
Texas
-
Laredo, Texas, United States, 78041
- Recruiting
- Oncology and Hematology of South Texas
-
Contact:
- Cesar Flores
- Phone Number: 872-222-7830
- Email: cesar.flores@prismsgrp.com
-
Principal Investigator:
- Eduardo Miranda, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient or representative provides written informed consent
- Patient is diagnosed with advanced malignancy
- Patient is willing to be treated for this malignancy according to a plan determine by them and their physician
- patient will be willing to have regular follow up visits as part of their standard of care
Exclusion Criteria:
- patient is not a candidate or does not desire any treatment for their disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Validation Cohort
Patients enrolled into the study to allow validation of a specific element, process, or endpoint.
Validation will be done showing concordance with traditional interventional trial standards.
|
Patients who have received biomarker testing that could affect prognosis or treatment decisions.
This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.
Other Names:
Patients who have received any treatment as part of their care.
This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.
Other Names:
|
Analysis Cohorts
Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit.
Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study.
Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
|
Patients who have received biomarker testing that could affect prognosis or treatment decisions.
This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.
Other Names:
Patients who have received any treatment as part of their care.
This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.
Other Names:
Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.
Other Names:
|
Retrospective Chart Review Cohorts
This arm will use retrospective data obtained through systematic chart review on previously seen patients to compare, contrast, or enhance the efforts of the prospective arms.
Because most RWD has been traditionally obtained through retrospective methods, this is also considered the "control arm."
Data in this arm will be collected without any patient identifiers.
This arm is optional.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall response (BOR) - 1st line of therapy
Time Frame: 1st line of therapy, on average less than 1 year
|
The best overall response for 1st line of therapy as determined by physician assessment
|
1st line of therapy, on average less than 1 year
|
Best overall response (BOR) - 2nd line of therapy
Time Frame: 2nd line of therapy, on average less than 1 year
|
The best overall response for 2nd line of therapy as determined by physician assessment
|
2nd line of therapy, on average less than 1 year
|
Best overall response (BOR) - 3rd line of therapy
Time Frame: 3rd line of therapy, on average less than 1 year
|
The best overall response for 3rd line of therapy as determined by physician assessment
|
3rd line of therapy, on average less than 1 year
|
Best overall response (BOR) - 4th line of therapy
Time Frame: 4th line of therapy, on average less than 1 year
|
The best overall response for 4th line of therapy as determined by physician assessment
|
4th line of therapy, on average less than 1 year
|
Best overall response (BOR) - 5th line of therapy
Time Frame: 5th line of therapy, on average less than 1 year
|
The best overall response for 5th line of therapy as determined by physician assessment
|
5th line of therapy, on average less than 1 year
|
Progression-free survival (PFS) - 1st line of therapy
Time Frame: 1st line of therapy, on average less than 1 year
|
The progression free survival for 1st line of therapy as determined by physician assessment
|
1st line of therapy, on average less than 1 year
|
Progression-free survival (PFS) - 2nd line of therapy
Time Frame: 2nd line of therapy, on average less than 1 year
|
The progression free survival for 2nd line of therapy as determined by physician assessment
|
2nd line of therapy, on average less than 1 year
|
Progression-free survival (PFS) - 3rd line of therapy
Time Frame: 3rd line of therapy, on average less than 1 year
|
The progression free survival for 3rd line of therapy as determined by physician assessment
|
3rd line of therapy, on average less than 1 year
|
Progression-free survival (PFS) - 4th line of therapy
Time Frame: 4th line of therapy, on average less than 1 year
|
The progression free survival for 4th line of therapy as determined by physician assessment
|
4th line of therapy, on average less than 1 year
|
Progression-free survival (PFS) - 5th line of therapy
Time Frame: 5th line of therapy, on average less than 1 year
|
The progression free survival for 5th line of therapy as determined by physician assessment
|
5th line of therapy, on average less than 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: through study completion, on average less than 3 years
|
The overall survival of a patient from the time of being diagnosed with advanced disease until death
|
through study completion, on average less than 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Razelle Kurzrock, MD, Moores Cancer Center at University of California at San Diego
- Principal Investigator: Raymond Bergan, MD, OHSU Knight Cancer Institute
- Principal Investigator: Vivek Subbiah, MD, M.D. Anderson Cancer Center
- Principal Investigator: Jennifer Johnson, MD, PhD, Sidney Kimmel Cancer Center at Thomas Jefferson University
Publications and helpful links
General Publications
- Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062. No abstract available.
- Boland JF, Chung CC, Roberson D, Mitchell J, Zhang X, Im KM, He J, Chanock SJ, Yeager M, Dean M. The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet. 2013 Oct;132(10):1153-63. doi: 10.1007/s00439-013-1321-4. Epub 2013 Jun 12.
- Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018 Sep 17;8(3):30. doi: 10.3390/jpm8030030.
- Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189.
- Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216. No abstract available.
- Kaplan RM, Chambers DA, Glasgow RE. Big data and large sample size: a cautionary note on the potential for bias. Clin Transl Sci. 2014 Aug;7(4):342-6. doi: 10.1111/cts.12178. Epub 2014 Jul 15.
- AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017 Aug;7(8):818-831. doi: 10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1.
- Dickson DJ, Pfeifer JD. Real-world data in the molecular era-finding the reality in the real world. Clin Pharmacol Ther. 2016 Feb;99(2):186-97. doi: 10.1002/cpt.300. Epub 2016 Jan 12.
- Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16;171(5):982-986. doi: 10.1016/j.cell.2017.10.032.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Disease Attributes
- Adnexal Diseases
- Gonadal Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Genital Neoplasms, Male
- Testicular Diseases
- Liver Diseases
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Myeloproliferative Disorders
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Parathyroid Diseases
- Otorhinolaryngologic Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Mouth Diseases
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Colonic Diseases
- Intestinal Diseases
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- DNA Virus Infections
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Bone Diseases
- Esophageal Diseases
- Pregnancy Complications
- Neoplasms, Plasma Cell
- Lung Neoplasms
- Fallopian Tube Diseases
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- Biliary Tract Diseases
- Leukemia, Lymphoid
- Herpesviridae Infections
- Pancreatic Diseases
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Vaginal Diseases
- Neoplasms, Vascular Tissue
- Neoplasm Metastasis
- Vulvar Diseases
- Adenoma
- Cecal Diseases
- Nasopharyngeal Neoplasms
- Pregnancy Complications, Neoplastic
- Ureteral Diseases
- Bile Duct Diseases
- Salivary Gland Diseases
- Neoplasms, Mesothelial
- Adrenal Gland Diseases
- Laryngeal Diseases
- Rectal Neoplasms
- Anus Diseases
- Neoplasms, Adipose Tissue
- Penile Diseases
- Infratentorial Neoplasms
- Mouth Neoplasms
- Biliary Tract Neoplasms
- Neoplasms, Multiple Primary
- Paraganglioma
- Tongue Diseases
- Cecal Neoplasms
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Sarcoma
- Stomach Neoplasms
- Testicular Neoplasms
- Head and Neck Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
- Glioblastoma
- Multiple Myeloma
- Leukemia
- Leukemia, Myeloid
- Fallopian Tube Neoplasms
- Thymus Neoplasms
- Bone Neoplasms
- Small Cell Lung Carcinoma
- Carcinoma, Adenoid Cystic
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Waldenstrom Macroglobulinemia
- Pancreatic Neoplasms
- Vulvar Neoplasms
- Cholangiocarcinoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Liver Neoplasms
- Osteosarcoma
- Astrocytoma
- Esophageal Neoplasms
- Colonic Neoplasms
- Trophoblastic Neoplasms
- Carcinoma, Small Cell
- Sarcoma, Kaposi
- Neuroendocrine Tumors
- Mesothelioma
- Ureteral Neoplasms
- Anus Neoplasms
- Neoplasms, Unknown Primary
- Liposarcoma
- Endocrine Gland Neoplasms
- Chondrosarcoma
- Vaginal Neoplasms
- Salivary Gland Neoplasms
- Uterine Neoplasms
- Carcinoid Tumor
- Pheochromocytoma
- Adrenal Gland Neoplasms
- Sarcoma, Synovial
- Penile Neoplasms
- Laryngeal Neoplasms
- Pharyngeal Neoplasms
- Parathyroid Neoplasms
- Bile Duct Neoplasms
- Multiple Endocrine Neoplasia
- Tongue Neoplasms
- Appendiceal Neoplasms
- Brain Stem Neoplasms
- Physiological Effects of Drugs
- Immunologic Factors
- Immunomodulating Agents
Other Study ID Numbers
- ROOT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
Clinical Trials on Biomarker Testing (L)
-
KU LeuvenCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
University of EdinburghNHS LothianCompletedPain | Toxicity Due to Radiotherapy | Cancer Induced Bone Pain | Secondary Malignant Neoplasm of BoneUnited Kingdom
-
M.D. Anderson Cancer CenterAlere San DiegoUnknownUnspecified Adult Solid Tumor, Protocol Specific | Cardiac ToxicityUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); North American Brain Tumor ConsortiumCompletedBrain and Central Nervous System Tumors | ThromboembolismUnited States
-
Zhongshan People's Hospital, Guangdong, ChinaActive, not recruiting
-
Unity Health TorontoHoffmann-La RocheUnknownStage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)Canada
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedSedentary Lifestyle | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC... and other conditionsUnited States
-
Queen's Medical CenterUnknownLung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Cachexia | Hematopoietic/Lymphoid Cancer | Gastrointestinal CancerUnited Kingdom
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completed